|Mr. Steven Saviuk||Chairman, Pres & CEO||344.07k||N/A||1959|
|Ms. Helen Saviuk||CFO & Director||167.5k||N/A||N/A|
|Mr. Ronald S. Perry CA, CPA||Sec.||N/A||N/A||1956|
|Mr. Marc LÃ©ger||Exec. VP of Commercial Operations - Valeo Pharma Inc||144.89k||N/A||N/A|
|Nathalie Therrien||Vice-Pres of QA & Regulatory Affairs - Valeo Pharma Inc.||135.17k||N/A||N/A|
|Mr. Luc Mainville M.B.A., M.B.A||Sr. VP & CFO of Valeo Pharma Inc||135k||N/A||1964|
|Mr. Kristof Biniecki||VP of Scientific Affairs - Valeo Pharma Inc||N/A||N/A||N/A|
Manitex Capital Inc. does not have significant business. It focuses on acquiring interests in life sciences, cleantech, and sustainable products/technologies companies. Previously, it was engaged in the acquisition and markets specialty pharmaceutical products, and distributes third-party pharmaceutical products, as well as holds a portfolio in marketable securities. The company is headquartered in Kirkland, Canada.
Manitex Capital Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.